Crossmark

Bigdata analytics identifies metabolic inhibitors and promoters for productivity improvement and optimization of monoclonal antibody (mAb) production process

Crossref DOI link: https://doi.org/10.1186/s40643-020-00318-6

Published Online: 2020-06-01

Published Print: 2020-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Morris, Caitlin

Polanco, Ashli

Yongky, Andrew

Xu, Jianlin

Huang, Zhuangrong

Zhao, Jia

McFarland, Kevin S.

Park, Seoyoung

Warrack, Bethanne

Reily, Michael

Borys, Michael C.

Li, Zhengjian

Yoon, Seongkyu http://orcid.org/0000-0002-5330-8784
Funding

Funding for this research was provided by:

Bristol-Myers Squibb
License Information

Text and Data Mining valid from 2020-06-01

Version of Record valid from 2020-06-01
More Information

Article History

Received: 23 January 2020

Accepted: 25 May 2020

First Online: 1 June 2020

Ethics approval and consent to participate

: Not applicable.

: Not applicable.

: Not applicable.

Document is current

Any future updates will be listed below